NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II Life Science Investing
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update Life Science Investing
Cizzle Brands Corporation Announces the Launch of CWENCH Hydration at Save-On-Foods Across Western Canada Biotech Investing
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology Life Science Investing
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation Life Science Investing
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+ Biotech Investing
Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026 Life Science Investing
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results Life Science Investing
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses Life Science Investing
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update Life Science Investing
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Life Science Investing
